- Home
- DVAX vs CMRE Comparison
DVAX vs CMRE Comparison
Compare DVAX & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- CMRE
- Stock Information
- Founded
- DVAX 1996
- CMRE 1974
- Country
- DVAX United States
- CMRE Monaco
- Employees
- DVAX N/A
- CMRE N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- CMRE Marine Transportation
- Sector
- DVAX Health Care
- CMRE Consumer Discretionary
- Exchange
- DVAX Nasdaq
- CMRE Nasdaq
- Market Cap
- DVAX 1.7B
- CMRE 1.9B
- IPO Year
- DVAX 2004
- CMRE 2010
- Fundamental
- Price
- DVAX $12.45
- CMRE $12.29
- Analyst Decision
- DVAX Buy
- CMRE Hold
- Analyst Count
- DVAX 2
- CMRE 2
- Target Price
- DVAX $23.00
- CMRE $13.50
- AVG Volume (30 Days)
- DVAX 1.8M
- CMRE 278.0K
- Earning Date
- DVAX 02-20-2025
- CMRE 02-05-2025
- Dividend Yield
- DVAX N/A
- CMRE 3.74%
- EPS Growth
- DVAX N/A
- CMRE N/A
- EPS
- DVAX 0.15
- CMRE 3.01
- Revenue
- DVAX $260,810,000.00
- CMRE $2,030,338,000.00
- Revenue This Year
- DVAX $21.64
- CMRE $19.29
- Revenue Next Year
- DVAX $19.81
- CMRE N/A
- P/E Ratio
- DVAX $82.38
- CMRE $4.09
- Revenue Growth
- DVAX N/A
- CMRE 58.37
- 52 Week Low
- DVAX $9.74
- CMRE $10.14
- 52 Week High
- DVAX $14.30
- CMRE $17.58
- Technical
- Relative Strength Index (RSI)
- DVAX 41.74
- CMRE 39.30
- Support Level
- DVAX $12.27
- CMRE $12.32
- Resistance Level
- DVAX $12.74
- CMRE $12.92
- Average True Range (ATR)
- DVAX 0.35
- CMRE 0.36
- MACD
- DVAX -0.06
- CMRE -0.01
- Stochastic Oscillator
- DVAX 37.39
- CMRE 1.63
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.